Literature DB >> 23294923

Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222.

Devashish Kothapalli1, Paola Castagnino, Daniel J Rader, Michael C Phillips, Sissel Lund-Katz, Richard K Assoian.   

Abstract

OBJECTIVE: In addition to its effects on cholesterol levels, apoE3 has lipid-independent effects that contribute to cardiovascular protection; one of these effects is the ability to inhibit cell cycling in VSMCs. The goal of this study was to identify and characterize cell cycle-regulatory mechanisms responsible for the anti-mitogenic effect of apoE. METHODS AND
RESULTS: Primary VSMCs were stimulated with serum in the absence or presence of apoE3. apoE3 upregulated expression of the cdk inhibitor, p27(kip1), in primary VSMCs, and this effect required Cox2 and activation of PGI(2)-IP signaling. The microRNA family, miR221/222 has recently been identified as a post-translational regulator of p27, and apoE3 inhibited miR221/222 expression in a Cox2- and PGI(2)/IP-dependent manner. Moreover, reconstituted miR222 expression was sufficient to override the effects of apoE on p27 expression and S phase entry. The ability to repress expression of miR221/222 is shared by apoE3-containing HDL but is absent from apoA-1, LDL and apoE-depleted HDL. All three apoE isoforms regulate miR221/222, and the effect is independent of the C-terminal lipid-binding domain. miR221/222 levels are increased in the aortae of apoE3-null mice and reduced when apoE3 expression is reconstituted by adeno-associated virus infection. Thus, regulation of miR221/222 by apoE3 occurs in vivo as well as in vitro.
CONCLUSIONS: ApoE inhibits VSMC proliferation by regulating p27 through miR221/222. Control of cell cycle-regulatory microRNAs adds a new dimension to the spectrum of cardiovascular protective effects afforded by apoE and apoE-HDL.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23294923      PMCID: PMC3638207          DOI: 10.1016/j.atherosclerosis.2012.12.003

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  37 in total

Review 1.  Regulation of the G1 to S transition by the ubiquitin pathway.

Authors:  L M DeSalle; M Pagano
Journal:  FEBS Lett       Date:  2001-02-16       Impact factor: 4.124

2.  Bench to bedside: the development of rapamycin and its application to stent restenosis.

Authors:  S O Marx; A R Marks
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

3.  Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation.

Authors:  D K Swertfeger; D Y Hui
Journal:  J Biol Chem       Date:  2001-05-11       Impact factor: 5.157

4.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

5.  Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth?

Authors:  L Paka; I J Goldberg; J C Obunike; S Y Choi; U Saxena; I D Goldberg; S Pillarisetti
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

6.  Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice.

Authors:  B Zhu; D G Kuhel; D P Witte; D Y Hui
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

7.  A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase.

Authors:  N P Malek; H Sundberg; S McGrew; K Nakayama; T R Kyriakides; J M Roberts; T R Kyriakidis
Journal:  Nature       Date:  2001-09-20       Impact factor: 49.962

8.  Effects of lipid interaction on the lysine microenvironments in apolipoprotein E.

Authors:  S Lund-Katz; M Zaiou; S Wehrli; P Dhanasekaran; F Baldwin; K H Weisgraber; M C Phillips
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

9.  The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis.

Authors:  A Díez-Juan; V Andrés
Journal:  FASEB J       Date:  2001-09       Impact factor: 5.191

10.  Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase.

Authors:  M Ishigami; D K Swertfeger; M S Hui; N A Granholm; D Y Hui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-04       Impact factor: 8.311

View more
  12 in total

1.  Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar).

Authors:  Xue Wang; Jin Niu; Jun Li; Xiaomeng Shen; Shichen Shen; Robert M Straubinger; Jun Qu
Journal:  Mol Cell Proteomics       Date:  2018-01-22       Impact factor: 5.911

Review 2.  Mechanotransduction and extracellular matrix homeostasis.

Authors:  Jay D Humphrey; Eric R Dufresne; Martin A Schwartz
Journal:  Nat Rev Mol Cell Biol       Date:  2014-10-22       Impact factor: 94.444

3.  microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis.

Authors:  Gaetano Santulli
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

4.  Apolipoprotein E3 Inhibits Rho to Regulate the Mechanosensitive Expression of Cox2.

Authors:  Bernadette Y Hsu; Yong Ho Bae; Keeley L Mui; Shu-Lin Liu; Richard K Assoian
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

5.  Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.

Authors:  Yanqing Zhang; Desheng Xu; Jiaqi Pan; Zhengkai Yang; Meijun Chen; Jun Han; Sijia Zhang; Lulu Sun; Hong Qiao
Journal:  Oncol Lett       Date:  2017-04-11       Impact factor: 2.967

6.  The inverted pattern of circulating miR-221-3p and miR-222-3p associated with isolated low HDL-C phenotype.

Authors:  Yuntao Zhou; Mengdi Liu; Jinrong Li; Bing Wu; Wei Tian; Lu Shi; Jing Zhang; Zening Sun
Journal:  Lipids Health Dis       Date:  2018-08-16       Impact factor: 3.876

Review 7.  Apolipoprotein E and Atherosclerosis: From Lipoprotein Metabolism to MicroRNA Control of Inflammation.

Authors:  Laura Bouchareychas; Robert L Raffai
Journal:  J Cardiovasc Dev Dis       Date:  2018-05-23

Review 8.  Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling.

Authors:  Dmitry A Chistiakov; Igor A Sobenin; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Biomed Res Int       Date:  2015-06-29       Impact factor: 3.411

9.  Recent exposure to ultrafine particles in school children alters miR-222 expression in the extracellular fraction of saliva.

Authors:  Annette Vriens; Tim S Nawrot; Nelly D Saenen; Eline B Provost; Michal Kicinski; Wouter Lefebvre; Charlotte Vanpoucke; Jan Van Deun; Olivier De Wever; Karen Vrijens; Patrick De Boever; Michelle Plusquin
Journal:  Environ Health       Date:  2016-07-26       Impact factor: 5.984

10.  Increased Expression of Resistin in MicroRNA-155-Deficient White Adipose Tissues May Be a Possible Driver of Metabolically Healthy Obesity Transition to Classical Obesity.

Authors:  Candice Johnson; Charles Drummer; Anthony Virtue; Tracy Gao; Susu Wu; Miguel Hernandez; Lexy Singh; Hong Wang; Xiao-Feng Yang
Journal:  Front Physiol       Date:  2018-10-12       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.